Get MindMed Updates:
with Psychedelic Inspired Medicines
zero to negligible hallucination effect
in accordance with diagnosis, for the purpose of healing
at-home use with daily or weekly administration
21 million Americans have at least one addiction, yet only 10% of those individuals receive treatment4. What’s worse is that often treatment comes with swapping one addictive substance for another. Addiction is a brain disease, driven by a single disease process: the dysregulation of dopamine, a potent neurotransmitter, in the brain’s reward/pleasure center located in the midbrain.
We are developing 18-MC to treat the cause of the brain disease that is addiction, rather than merely substituting one addictive substance for another less harmful one. Sustained mental healing requires addressing the root cause and a comprehensive approach for the entire patient journey.
Cue-induced reinstatement, or relapse, is when an addict is prompted by their surroundings to consume a harmful substance (example: The clink of a wine glass at a dinner party for an alcoholic).
Our intent is not to put people on a pill a day for the rest of their lives, we want to solve for the one of the most common challenging parts of addiction, cue-induced relapse
Dr. Stanley Glick (Chair of MindMed’s Scientific Advisory Board) invented 18-MC as a solution for addiction.
Ibogaine is a Schedule 1 substance extracted from the West Africa iboga shrub with anti-addictive properties but has potential to induce heart attacks
Our scientists and chemists have invented a better version of ibogaine, a derivative called 18-MC
Designed to correct the dysregulation in the brain’s reward/pleasure center to treat addiction without the hallucinogenic and potential negative side effects of ibogaine
Our [MindMed’s] approach to addiction is, why not treat the cause of the disease in the brain as opposed to using less effective substitution and aversion therapies or intervening at the point at which you’re providing a life-saving measure?”
Adult suffering in US from ADHD5
Adults with ADHD who are receiving treatment6
Between 2007 and 2016 alone, the rate amongst adults increased by 123%. 7
Microdosing refers to a smaller, non-hallucinogenic dose of LSD. In these cases, the medicinal properties of the compound address the illness and may not require a hallucinogenic dose as a component of healing.
Extensive anecdotal evidence suggests microdosing Psilocybin & LSD may:
Rigorous scientific trials are in progress to validate these claims and ensure the highest standards of quality, safety, and efficacy for medical use if approved. This is where MindMed’s Microdosing Division comes in.